Text this: Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma